Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07073924 · ClinicalTrials.gov registry record · NA
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
A NA study, sponsored by University of Pittsburgh.
- Not yet
- Registry status
- NA
- Development phase
- 536
- Enrollment target
NCT07073924: Clinical Trial NA study, sponsored by University of Pittsburgh.
NCT07073924 is a NA study that has not yet begun recruiting, run by University of Pittsburgh. The registered enrollment target is 536 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07073924, a NA study, has not yet begun recruiting, sponsored by University of Pittsburgh.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 536 participants
- Enrollment target
Study Summary
In the U.S., an estimated 3.6 million people who inject drugs (PWID) face a growing yet preventable health crisis, with rising cases of serious injection-related infections (SIRI), including HIV, due to limited access to two high-priority interventions: sterile injection equipment and daily oral HIV pre-exposure prophylaxis (PrEP). Outpatient clinics represent an opportune venue to implement these interventions. Yet most clinical providers in these settings do not currently provide them, contributing to a wide gap between evidence and routine practice. The Prescribe to Prevent HIV (P2PH) trial is a participatory study designed to co-develop and pilot test a set of implementation strategies to support outpatients clinics in offering sterile injection equipment and PrEP with the goal of reducing the risk of HIV and SIRI among PWID. This study is supported by the HEAL Initiative (https://heal.nih.gov/).
Primary Outcome
This is defined as the proportion of clinicians who prescribed injection equipment and/or PrEP per site, assessed at 6 months post-implementation, respectively using electronic health record data.
Interventions
- BEHAVIORAL Implementation strategy bundle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 536 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2028-06 |
| Phase | NA |
What is known before NCT07073924 opens enrollment
NCT07073924 is an interventional study that assigns participants to a tested intervention. The registered 536 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Implementation strategy bundle is the first listed.
NCT07073924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07073924 about?
NCT07073924 is a clinical study titled "Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support". In the U.S., an estimated 3.6 million people who inject drugs (PWID) face a growing yet preventable health crisis, with rising cases of serious injection-related infections (SIRI), including HIV, due to limited access to two high-priority interventions: sterile injection equipment and daily oral HIV...
What is the current status of trial NCT07073924?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 536 participants. The study started on 2026-08-01. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07073924?
The interventions under investigation include: Implementation strategy bundle (BEHAVIORAL).
Who is sponsoring clinical trial NCT07073924?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07073924's enrollment target sits among peer trials
536 188th of 2000 higher than 1,813 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI